[1]
|
Eslam, M., Newsome, P.N., Sarin, S.K., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. https://doi.org/10.1016/j.jhep.2020.03.039
|
[2]
|
Nassir, F. (2022) NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules, 12, Article No. 824. https://doi.org/10.3390/biom12060824
|
[3]
|
Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2012) The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 142, 1592-1609. https://doi.org/10.1053/j.gastro.2012.04.001
|
[4]
|
Teli, M.R., James, O.F., Burt, A.D., et al. (1995) The Natural History of Nonalcoholic Fatty Liver: A Follow-Up Study. Hepatology, 22, 1714-1719. https://doi.org/10.1002/hep.1840220616
|
[5]
|
Ekstedt, M., Hagström, H., Nasr, P., et al. (2015) Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD after up to 33 Years of Follow-Up. Hepatology, 61, 1547-1554. https://doi.org/10.1002/hep.27368
|
[6]
|
Pais, R., Charlotte, F., Fedchuk, L., et al. (2013) A Systematic Review of Follow-Up Biopsies Reveals Disease Progression in Patients with Non-Alcoholic Fatty Liver. Journal of Hepatology, 59, 550-556. https://doi.org/10.1016/j.jhep.2013.04.027
|
[7]
|
Singh, S., Allen, A.M., Wang, Z., et al. (2015) Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology, 13, 643-654.E1-9. https://doi.org/10.1016/j.cgh.2014.04.014
|
[8]
|
Younossi, Z., Anstee, Q.M., Marietti, M., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 15, 11-20. https://doi.org/10.1038/nrgastro.2017.109
|
[9]
|
Pais, R., Barritt, A.S.T., Calmus, Y., et al. (2016) NAFLD and Liver Transplantation: Current Burden and Expected Challenges. Journal of Hepatology, 65, 1245-1257. https://doi.org/10.1016/j.jhep.2016.07.033
|
[10]
|
Fitzmaurice, C., Abate, D., Abbasi, N., et al. (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 5, 1749-1768. https://doi.org/10.1001/jamaoncol.2019.2996
|
[11]
|
Allen, A.M., Lazarus, J.V. and Younossi, Z.M. (2023) Healthcare and Socioeconomic Costs of NAFLD: A Global Framework to Navigate the Uncertainties. Journal of Hepatology, 79, 209-217. https://doi.org/10.1016/j.jhep.2023.01.026
|
[12]
|
Huh, Y., Cho, Y.J. and Nam, G.E. (2022) Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. Journal of Obesity & Metabolic Syndrome, 31, 17-27. https://doi.org/10.7570/jomes22021
|
[13]
|
Fujimoto, M. and Naka, T. (2010) SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases. Gastroenterology Research and Practice, 2010, Article ID: 470468. https://doi.org/10.1155/2010/470468
|
[14]
|
Berntorp, E., Petrini, P., Dockter, G., et al. (2001) An Approach to Study the Viral Safety of Plasma-Derived Products in Previously Treated, Non-Infected Patients. Haemophilia, 7, 360-363. https://doi.org/10.1046/j.1365-2516.2001.00522.x
|
[15]
|
Li, X., Liu, X., Tian, L., et al. (2016) Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clinical Reviews in Allergy & Immunology, 50, 41-54. https://doi.org/10.1007/s12016-014-8465-4
|
[16]
|
Galic, S., Sachithanandan, N., Kay, T.W., et al. (2014) Suppressor of Cytokine Signalling (SOCS) Proteins as Guardians of Inflammatory Responses Critical for Regulating Insulin Sensitivity. Biochemical Journal, 461, 177-188. https://doi.org/10.1042/BJ20140143
|
[17]
|
Kempinska-Podhorodecka, A., Milkiewicz, M., Wasik, U., et al. (2017) Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-MiRNA155-SOCS1 Pathway. International Journal of Molecular Sciences, 18, Article No. 289. https://doi.org/10.3390/ijms18020289
|
[18]
|
Kang, I., Kim, J.A., Kim, J., et al. (2022) Hepatitis B Virus X Protein Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Regulating SOCS1. BMB Reports, 55, 220-225. https://doi.org/10.5483/BMBRep.2022.55.5.157
|
[19]
|
Adams, L.A., Lymp, J.F., St Sauver, J., et al. (2005) The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology, 129, 113-121. https://doi.org/10.1053/j.gastro.2005.04.014
|
[20]
|
Eslam, M., Sanyal, A.J. and George, J. (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 158, 1999-2014.E1. https://doi.org/10.1053/j.gastro.2019.11.312
|
[21]
|
Ogden, C.L., Carroll, M.D., Kit, B.K., et al. (2014) Prevalence of Childhood and Adult Obesity in the United States, 2011-2012. JAMA, 311, 806-814. https://doi.org/10.1001/jama.2014.732
|
[22]
|
Vernon, G., Baranova, A. and Younossi, Z.M. (2011) Systematic Review: The Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in Adults. Alimentary Pharmacology & Therapeutics, 34, 274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
|
[23]
|
Loomba, R., Lim, J.K., Patton, H., et al. (2020) AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 158, 1822-1830. https://doi.org/10.1053/j.gastro.2019.12.053
|
[24]
|
Masuoka, H.C. and Chalasani, N. (2013) Nonalcoholic Fatty Liver Disease: An Emerging Threat to Obese and Diabetic Individuals. Annals of the New York Academy of Sciences, 1281, 106-122. https://doi.org/10.1111/nyas.12016
|
[25]
|
Almeida, E.A., Mehndiratta, M., Madhu, S.V., et al. (2022) Differential Expression of Suppressor of Cytokine Signaling and Interferon Gamma in Lean and Obese Patients with Type 2 Diabetes Mellitus. International Journal of Endocrinology and Metabolism, 20, E122553. https://doi.org/10.5812/ijem-122553
|
[26]
|
Feng, X., Tang, H., Leng, J., et al. (2014) Suppressors of Cytokine Signaling (SOCS) and Type 2 Diabetes. Molecular Biology Reports, 41, 2265-2274. https://doi.org/10.1007/s11033-014-3079-8
|
[27]
|
Xu, C.H., Liu, Y., Xiao, L.M., et al. (2019) Silencing MicroRNA-221/222 Cluster Suppresses Glioblastoma Angiogenesis by Suppressor of Cytokine Signaling-3-Dependent JAK/STAT Pathway. Journal of Cellular Physiology, 234, 22272-2284. https://doi.org/10.1002/jcp.28794
|
[28]
|
Doggett, K., Keating, N., Dehkhoda, F., et al. (2023) The SOCS1 KIR and SH2 Domain Are both Required for Suppression of Cytokine Signaling in Vivo. Cytokine, 165, Article ID: 156167. https://doi.org/10.1016/j.cyto.2023.156167
|
[29]
|
Endo, T.A., Masuhara, M., Yokouchi, M., et al. (1997) A New Protein Containing an SH2 Domain That Inhibits JAK Kinases. Nature, 387, 921-924. https://doi.org/10.1038/43213
|
[30]
|
Chu, P.Y., Yeh, C.M., Hsu, N.C., et al. (2010) Epigenetic Alteration of the SOCS1 Gene in Hepatocellular Carcinoma. Swiss Medical Weekly, 140, W13065. https://doi.org/10.4414/smw.2010.13065
|
[31]
|
Okochi, O., Hibi, K., Sakai, M., et al. (2003) Methylation-Mediated Silencing of SOCS-1 Gene in Hepatocellular Carcinoma Derived from Cirrhosis. Clinical Cancer Research, 9, 5295-5298.
|
[32]
|
Li, Z., Metze, D., Nashan, D., et al. (2004) Expression of SOCS-1, Suppressor of Cytokine Signalling-1, in Human Melanoma. Journal of Investigative Dermatology, 123, 737-745. https://doi.org/10.1111/j.0022-202X.2004.23408.x
|
[33]
|
Huang, F.J., Steeg, P.S., Price, J.E., et al. (2008) Molecular Basis for the Critical Role of Suppressor of Cytokine Signaling-1 in Melanoma Brain Metastasis. Cancer Research, 68, 9634-9642. https://doi.org/10.1158/0008-5472.CAN-08-1429
|
[34]
|
Oshimo, Y., Kuraoka, K., Nakayama, H., et al. (2004) Epigenetic Inactivation of SOCS-1 by CpG Island Hypermethylation in Human Gastric Carcinoma. International Journal of Cancer, 112, 1003-1009. https://doi.org/10.1002/ijc.20521
|
[35]
|
Shao, N., Ma, G., Zhang, J., et al. (2018) MiR-221-5p Enhances Cell Proliferation and Metastasis through Post-Transcriptional Regulation of SOCS1 in Human Prostate Cancer. BMC Urology, 18, Article No. 14. https://doi.org/10.1186/s12894-018-0325-8
|
[36]
|
Davey, G.M., Starr, R., Cornish, A.L., et al. (2005) SOCS-1 Regulates IL-15-Driven Homeostatic Proliferation of Antigen-Naive CD8 T Cells, Limiting Their Autoimmune Potential. Journal of Experimental Medicine, 202, 1099-1108. https://doi.org/10.1084/jem.20050003
|
[37]
|
Alexander, W.S., Starr, R., Fenner, J.E., et al. (1999) SOCS1 Is a Critical Inhibitor of Interferon Gamma Signaling and Prevents the Potentially Fatal Neonatal Actions of This Cytokine. Cell, 98, 597-608. https://doi.org/10.1016/S0092-8674(00)80047-1
|
[38]
|
Chong, M.M., Cornish, A.L., Darwiche, R., et al. (2003) Suppressor of Cytokine Signaling-1 Is a Critical Regulator of Interleukin-7-Dependent CD8 T Cell Differentiation. Immunity, 18, 475-487. https://doi.org/10.1016/S1074-7613(03)00078-5
|
[39]
|
Starr, R., Metcalf, D., Elefanty, A.G., et al. (1998) Liver Degeneration and Lymphoid Deficiencies in Mice Lacking Suppressor of Cytokine Signaling-1. Proceedings of the National Academy of Sciences of the United States of America, 95, 14395-14399. https://doi.org/10.1073/pnas.95.24.14395
|
[40]
|
Gylvin, T., Ek, J., Nolsøe, R., et al. (2009) Functional SOCS1 Polymorphisms Are Associated with Variation in Obesity in Whites. Diabetes, Obesity and Metabolism, 11, 196-203. https://doi.org/10.1111/j.1463-1326.2008.00900.x
|
[41]
|
Kempinska-Podhorodecka, A., Wunsch, E., Milkiewicz, P., et al. (2019) The Association Between SOCS1-1656G > A Polymorphism, Insulin Resistance and Obesity in Nonalcoholic Fatty Liver Disease (NAFLD) Patients. Journal of Clinical Medicine, 8, Article No. 1912. https://doi.org/10.3390/jcm8111912
|